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We report a 29-year-old gravida 2, para 0100,whopresented at 19weeks and 4days of gestation for ultrasound to assess fetal anatomy.
Routine midtrimester fetal anatomy ultrasound revealed enlarged, hyperechoic fetal kidneys and normal amniotic fluid index.
Follow-up ultrasound at 23weeks and 5 days revealed persistently enlarged, hyperechoic fetal kidneys. Progressive oligohydramnios
was not evident until 29 weeks of gestation, with anhydramnios noted by 35 weeks of gestation. Amniocentesis was performed
for karyotype and to search for mutations in the PKHD1 for the presumptive diagnosis of autosomal recessive polycystic kidney
disease (ARPKD). In our patient, a maternally inherited, previously reported pathogenic missense mutation in the PKHD1 gene,
c.10444C>T, was identified. A second, previously unreported de novo mutation, c.5909-2delA, was also identified. This mutation
affects the canonical splice site and is most likely pathogenic. Our case highlights PKHD1 allelic heterogeneity and the importance
of genetic testing in the prenatal setting where many other genetic etiologies can phenocopy ARPKD.
1. Introduction
Autosomal recessive polycystic kidney disease (ARPKD;
OMIM number 263200) is a single gene, severe hereditary
form of polycystic kidney and liver disease caused by muta-
tions in the PKHD1 gene. It has an estimated incidence of
1 : 40,000 [1] and a carrier frequency of 1 in 100 [2]. ARPKD
accounts for approximately 2-3% of the polycystic disease
affecting the kidneys, with 75 to 80 percent of cases mani-
festing in the neonatal period [3]. PKHD1 gene has a compli-
cated transcription profile and undergoes complex alternative
splicing that generates multiple variants of the fibrocystin/
polyductin (FC/PD) protein [4, 5]. Given that mutations
are spread throughout the PKHD1 gene and not clustered
at a region, the clinical outcome may be difficult to predict
based on the molecular genetic data alone. Because most
of the PKHD1 mutations are unique to individual fami-
lies, genotype-phenotype correlation is not well established.
Approximately 30 to 50 percent of newborns die shortly after
birth, secondary to pulmonary hypoplasia [6]. The perinatal
form of ARPKD usually presents at birth with bilateral
enlarged cystic kidneys leading to severe renal failure. Ante-
natal ultrasound has remarkably improved our understand-
ing of the natural history of the disease. Many cases present
in the second trimester of pregnancy with enlarged, hyper-
echoic kidneys, accompanied by oligohydramnios or even
anhydramnios. Progressive oligohydramnios may lead to
positional limb deformities, flattened facial profile with broad
nasal bridge, recessed chin, pseudoepicanthic folds, and pul-
monary hypoplasia, also known as Potter sequence in severely
affected fetuses. However, mutations in HNF1B or genes that
typically cause other ciliopathies, such as nephronophthisis,
Bardet Biedl, Joubert syndrome, and related disorders, can
mimic ARPKD. Prenatal ultrasound based renal phenotyp-
ing cannot accurately distinguish between different genetic
etiologies and genetic testing is therefore critical to make
accurate diagnosis that can affect obstetric and neonatal
management.
We present a case of ARPKD, initially diagnosed at 19
weeks and 4 days of gestation by ultrasound. The newborn
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died of pulmonary hypoplasia soon after delivery, likely sec-
ondary to oligohydramnios first identified at approximately
29 weeks of gestation. PKHD1mutational analysis revealed a
maternally inherited c.10444C>T recurrent missense muta-
tion, previously reported to be associated with ARPKD [7].
An additional, previously unreported, de novo mutation,
c.5909-2delA,was also present. Our case report highlights the
importance of routine antenatal ultrasound and molecular
genetic testing in clinically diagnosing ARPKD to establish
appropriate prenatal management.
2. Material and Methods
Chromosome analysis was performed on metaphase spreads
prepared from the cultured amniotic fluid specimen using
standard laboratory protocols at the Pittsburgh Cytogenetics
Laboratory. Fifteen cells were analyzed at the 500 G-band
level of resolution to determine karyotype. Targeted muta-
tional analysis for the PKHD1 gene was performed by PCR
based exon amplification and direct bidirectional sequencing
of both strands of all 67 PKHD1 exons at the Medical
Genomics Laboratory, University of Alabama at Birming-
ham.
3. Clinical Report
The proband is a 29-year-old gravida 2, para 0100, who
presented at 19 weeks and 4 days of gestation for routine
ultrasound to assess fetal anatomy. She and her husband
were healthy and nonconsanguineous and denied exposure
to any teratogens. A three-generation pedigree did not reveal
significant history of renal disease. Her obstetric history was
significant for a previous pregnancy with loss of a fetus with
an omphalocele at 18 weeks of gestational age and normal
chromosomal microarray.
The current pregnancy began uneventfully until routine
midtrimester fetal anatomy ultrasound revealed enlarged,
hyperechoic kidneys.The renal volume bilaterally was greater
than the 90th percentile for gestational age (Figures 1(a) and
1(b)).
The remaining fetal biometry and anatomy survey was
unremarkable. The ultrasound findings were suspicious for
ARPKD. The amniotic fluid level of 145mm, however, was
within normal limits for gestational age. The follow-up
ultrasound at 23 weeks and 5 days revealed persistently
enlarged and hyperechoic fetal kidneys with normal amniotic
fluid index measuring 115mm. The patient was counseled
regarding the suspicion for ARPKD and given options for
genetic testing. She elected to undergo amniocentesis for fetal
karyotype and mutation detection in the PKHD1 gene for the
presumptive diagnosis of ARPKD at 26 weeks and 4 days of
gestational age. She elected to continue the pregnancy and
was followed through the Center for Advanced Fetal Diag-
nostics at Magee-Womens Hospital. Karyotype was normal
46, XX. Mutation analysis of the PKHD1 gene revealed a
maternally inherited and previously reported c.10444C>T
(p.Arg3482Cys) missense mutation and a novel, previously
unreported de novo splice site mutation, c.5909-2delA.
(a)
(b)
Figure 1: (a) Coronal images of the fetal kidneys at 19 weeks and
4 days of gestation. The kidneys are enlarged and echogenic. (b)
Transverse images of the fetal kidneys at 19 weeks and 4 days of
gestation. The amniotic fluid level was normal for gestational age.
Follow-up ultrasound arranged at 2-week intervals
revealed persistent, enlarged, and hyperechoic kidneys, with
oligohydramnios (AFI 46mm), first identified at 29 weeks
(Figures 2(a) and 2(b)), followed by anhydramnios identified
at 35 weeks of gestation (Figures 3(a) and 3(b)). Fetal growth
was noted to be appropriate throughout gestation (Table 1).
At 29 weeks of gestation, the fetal abdominal circumfer-
ence was noted to be at the 90th percentile for gestational
age, and by 32 weeks, the fetal abdominal circumference
measured greater than the 97th percentile, likely due to the
enlarged kidneys. A 3366-gram female neonate with APGAR
scores of 4 and 8 at 1 and 5 minutes, respectively, was
delivered vaginally at 35weeks and 5 days following induction
of labor. The newborn required intubation for respiratory
distress at two minutes after delivery. The neonate continued
to have persistent hypoxemia and hypercarbia despite aggres-
sive mechanical ventilation. Chest X-rays done after birth
revealed low lung volumes with bilateral pneumothorax. The
family elected for palliative care and the newborn was extu-
bated approximately three hours following delivery and died
soon thereafter. An autopsy was offered, which the family
declined.
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(a)
(b)
Figure 2: (a) Longitudinal images of the fetal kidneys at 29 weeks
and 1 day of gestation. The kidneys continue to be enlarged and
echogenic in appearance. Oligohydramnios was noted at the time
of this ultrasound. (b) Transverse images of the fetal kidneys at 29
weeks and 1 day of gestation.
4. Discussion
ARPKD is caused by mutations in the PKHD1 gene, which
maps to chromosome 6p21.1-p12. PKHD1 is amongst the
largest genes in humanswith 66 coding exons [5] and encodes
a 4074-amino acid protein named fibrocystin/polyductin
(FC/PD). FC/PD is expressed in kidneys, adrenal glands,
liver, and pancreas. FC/PD is a single transmembrane domain
protein with a short intracellular carboxy terminus and a
large extracellular amino terminus [5]. FC/PD has been
shown to be localized to the primary cilia with concentrations
in the basal body [8, 9].Mutationswithin FC/PDcause abnor-
mal epithelial differentiation, followed by increased apoptosis
and fluid secretion that ultimately lead to clinically detectable
cyst formation [6, 10]. Due to high incidence of private
mutations, the clinical outcome is not predictable based on
the molecular genetic data. The reported mutation detection
rate is about 80 percent for the entire clinical spectrum of
ARPKD patients [1, 2]. The rest of the mutations are likely
in the regulatory regions that are not captured by current
sequencing strategies.
(a)
(b)
Figure 3: (a) Longitudinal image of the fetal right kidney at 35weeks
and 1 day of gestation. Notice the significantly enlarged renal size.
(b) Transverse image of the fetal kidneys at 35 weeks and 1 day.
Notice how the kidneys essentially occupy the entire fetal abdomen.
Anhydramnios was noted at this gestational age.
In our case, mutational analysis of the PKHD1 gene
revealed a maternally inherited c.10444C>T (p.Arg3482Cys)
missense mutation in the PKHD1 gene, reported several
times in the literature and, in all cases, as pathogenic.
However, a second previously unreported de novo c.5909-
2delA splicing mutation was also found and inherited pater-
nally. The c.5909-2delA variant is not present in the exome
variant server, dbSNP135, or HGMD. The c.5909-2delA
mutation disrupts the exon 37 splice acceptor canonical site.
The exon 37 splice acceptor site is conserved in frogs
and other vertebrates. The next predicted splice accep-
tor site (http://www.fruitfly.org/seq tools/splice.html) is 25-
nucleotide downstream and leads to premature stop codon
insertion. The mutation is therefore likely to produce trun-
cated protein product. Carrying two truncating mutations is
usually lethal, whereas the presence of at least one missense
mutation is compatible with life due to residual functioning
fibrocystin protein [6]. In our case, onemutation is previously
reported missense while the other is predicted to be a novel
splice mutation. Homozygous p.Arg3482Cys missense muta-
tion was previously reported to be associated with perinatal
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lethal phenotype in two consanguineous Israel-Arab families
[7]. It is therefore not surprising that missense p.Arg3482Cys
and splicing c.5909-2delA mutations led to perinatal mortal-
ity.
The fetus in our case was suspected to have ARPKD on
routine fetal anatomy ultrasound. However, it is important
to emphasize that other genetic etiologies can phenocopy
ARPKD renal findings. These disorders include HNF1B and
the diverse group of ciliopathies, such as nephronophthisis,
Bardet Biedl, and Joubert syndrome. The antenatal imaging
modality of choice to monitor for progression of disease
is serial ultrasound assessment of the fetus. MRI has also
been used for better phenotyping of renal anatomy. MRI
will show enlarged kidneys with hyperintense T2-weighted
signals in ARPKD cases [11]. MRI may be more sensitive
than ultrasound in differentiating between the cysts, normal
parenchyma, and fibrosis, although higher cost limits its use
in prenatal imaging. In the present case, follow-up ultrasound
at 2-week intervals revealed progressively declining amniotic
fluid, with oligohydramnios beginning at 29 weeks and
anhydramnios by 35 weeks of gestation.
Thirty percent of the newborns diagnosed with ARPKD
die during the neonatal period due to pulmonary hypoplasia.
The use of a ventilator has been suggested as a prognostic
marker indicative of lower survival [2, 3]. After the baby
is born, resuscitation is the key, as well as careful physical
examination to rule out other structural birth defects that
may point to etiologies other than ARPKD. Our patient had
severe respiratory distress at the time of delivery. Following
intubation, the newborn required high ventilator settings but
had persistent hypoxemia and hypercarbia and subsequently
developed bilateral pneumothoraces, all related to underlying
pulmonary hypoplasia. Survival past the neonatal period
has a more favorable outcome, with 10-year survival rate of
approximately 82 percent [12]
Given the poor prognosis and severity of ARPKD, the
option of prenatal testing in pregnancy and preimplantation
genetic diagnosis (PGD) in any subsequent pregnancies must
be discussed in couples known to be carriers of ARPKD
mutations. PGD using a single embryo genome amplification
with multiple displacement amplification (MDA) and haplo-
type analysis with novel short tandem repeat (STR) markers
from the PKHD1 gene have been successfully done in the
past for known mutations [13, 14]. ARPKD has a variable
clinical spectrum, but in a given family, patients usually
display comparable phenotypes.The affected newborn in our
case was the first affected member of the family. With more
cases of ARPKD being diagnosed prenatally, there is ongoing
research for therapies to halt disease progression in the future,
but currently none is available.
Our case emphasizes the importance of prenatal diag-
nosis of renal abnormalities by routine fetal anatomic ultra-
sound and genetic testing for ARPKD. Because other con-
ditions can mimic ARPKD, the use of genetic panels will
likely become the preferred option for genetic testing. Our
study presents a detailed change in the fetal biometry over the
prenatal course of the perinatal ARPKD with a novel splice
mutation. In our case, oligohydramnios was not present until
29 weeks of gestational age, followed by anhydramnios. The
earlier oligohydramnios or anhydramnios is diagnosed, the
higher likelihood of a poor neonatal outcome is.
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